Navigation Links
John Timberlake, Valeritas' Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
Date:10/23/2007

PARSIPPANY, N.J., Oct. 23 /PRNewswire/ -- Valeritas, LLC, a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that John Timberlake, Executive Vice President and General Manager of Valeritas, LLC was awarded the distinguished Executive of Year award by the Diabetes Foundation, an organization dedicated to the needs of patients with diabetes in New Jersey.

"John's continued commitment to improving the quality of care for patients with diabetes made him an obvious choice for Executive of the Year," said Sam Fusco, Chairman of the Board of the Diabetes Foundation. "We are honored to have John among this elite group of executives, and look forward to working with him to improve the lives of people suffering with diabetes in New Jersey."

Mr. Timberlake has devoted nearly half of his 21-year career to the commercialization of new treatments for patients with diabetes. In his current role at Valeritas, he is focused on commercializing and launching the lead product in the Valeritas portfolio -- the h-Patch(TM) disposable insulin delivery device, a once-daily, simple-to-use, discreet insulin delivery device that provides both a continuous set basal rate of insulin and on-demand bolus dosing for mealtime coverage. The h-Patch(TM) is expected to be available in the New Jersey area in the first half of 2008 and nationally by the end of 2008.

"I am very honored to accept this award from an organization dedicated to the fight against diabetes," said Mr. Timberlake. "While there have been great strides in improving treatment options for people with diabetes and there is less stigma about taking insulin, more needs to be done. At Valeritas, the h-Patch(TM) technology has been designed to provide patients with a drug delivery option that mimics the physiologic distribution of insulin in a simple fashion which will improve compliance and ultimately lead to better control. I am confident the advances that Valeritas will make in the area of diabetes will help patients in New Jersey and around the country."

About Valeritas, LLC

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that directly improve clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch(TM) insulin delivery system. The h-Patch(TM) is a simple-to- use, once-daily disposable basal and on-demand bolus delivery system that will enable the millions suffering from Type 2 diabetes to discreetly and conveniently deliver insulin throughout the day, including around meals. Developed to help enhance a patient's glycemic control, the h-Patch(TM) is the smallest known FDA-cleared insulin delivery system with basal-bolus capability and no visible needle. The h-Patch(TM) has received FDA 510(k) clearance and Phase IV clinical trials are running to support broad marketing and reimbursement claims. In addition to h-Patch(TM) for the delivery of insulin, Valeritas' delivery technology portfolio includes h-Patch(TM) for the delivery of other compounds beyond insulin, e-Patch(TM) Controlled Release Disposable Micro Pump System, Mini-Ject(TM) Pre-Filled Needle-Free Delivery System and the Micro-Trans(TM) Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

Headquartered in Parsippany, N.J., Valeritas operates its R&D and clinical manufacturing in a state-of-the-art manufacturing and R&D facility in Shrewsbury, Mass.

About the Diabetes Foundation

The Diabetes Foundation, Inc. is a 501(c)(3) organization incorporated in New Jersey and traces its origins to 1990 when its founders, all active in the American Diabetes Association (ADA), decided that they wanted to have a greater impact by investing in the needs of diabetics in the state of New Jersey. The Foundation, based in Ridgewood, New Jersey, offers programs and services to people suffering from diabetes. The Diabetes Foundation supports a variety of programs and services, including: medical assistant programs; educational series for patients, caregivers and healthcare professionals; subsidizes the cost of sending children with diabetes to a co-ed diabetes camp; and provides annual grants to local endocrine fellows concentrating in diabetes. For more information, visit http://www.DiabetesInNJ.org.


'/>"/>
SOURCE Valeritas, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Visions: Matheys says CIO role is good training for executive suite
3. Biotech executive books a career flight thats closer to home
4. CEOs Gone Wild? Risks and rewards in the executive suite
5. Early-stage executives hear from investors
6. Pedlar the latest executive to leave Merge
7. Financial executives to launch Madison chapter
8. Former Thompson lawyer comments on Doyle stem cell executive order
9. Republican sees nothing wrong with Doyles use of executive order
10. Executives hear about promise, limits of RFID and nanotech
11. RoleFlow launches process-management software for executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
Breaking Biology News(10 mins):